SCYNEXIS, Inc. (SCYX) financial statements (2021 and earlier)
Company profile
| Business Address |
1 EVERTRUST PLAZA JERSEY CITY, NJ 07302-6548 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 48 | 28 | 35 | 39 | 44 | 49 | 55 | ||
| Cash and cash equivalents | 42 | 12 | 19 | 13 | 11 | 16 | 7 | ||
| Short-term investments | 6 | 16 | 16 | 26 | 33 | 33 | 48 | ||
| Restricted cash and investments | 0 | 0 | 0 | 0 | |||||
| Receivables | 0 | 0 | |||||||
| Prepaid expense | 0 | 1 | 1 | 0 | 0 | 0 | 0 | ||
| Other current assets | 1 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other undisclosed current assets | 3 | 0 | 0 | 1 | 7 | 0 | 1 | ||
| Total current assets: | 52 | 29 | 36 | 40 | 51 | 50 | 57 | ||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 3 | 3 | ✕ | ✕ | ✕ | ||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Restricted cash and investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Deferred costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Other noncurrent assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||
| Other undisclosed noncurrent assets | 3 | 3 | |||||||
| Total noncurrent assets: | 5 | 5 | 5 | 5 | 2 | 1 | 2 | ||
| TOTAL ASSETS: | 57 | 34 | 41 | 45 | 53 | 52 | 58 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 11 | 8 | 7 | 5 | 6 | 3 | 4 | ||
| Accounts payable | 7 | 6 | 4 | 2 | 4 | 2 | 3 | ||
| Accrued liabilities | 4 | 2 | 3 | 2 | 2 | 1 | 2 | ||
| Debt | 0 | 0 | 7 | 5 | |||||
| Derivative instruments and hedges, liabilities | 0 | 3 | |||||||
| Other undisclosed current liabilities | 0 | 0 | 0 | 0 | 0 | ||||
| Total current liabilities: | 11 | 8 | 7 | 5 | 6 | 11 | 13 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 3 | 3 | 15 | 8 | 9 | ||||
| Long-term debt, excluding current maturities | 15 | 8 | 9 | ||||||
| Operating lease, liability | 3 | 3 | ✕ | ✕ | ✕ | ||||
| Other undisclosed noncurrent liabilities | 30 | 16 | 23 | 29 | 1 | 5 | 9 | ||
| Total noncurrent liabilities: | 33 | 20 | 23 | 29 | 16 | 13 | 18 | ||
| Total liabilities: | 44 | 28 | 31 | 34 | 22 | 24 | 31 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | 13 | 6 | 10 | 11 | 31 | 28 | 27 | ||
| Additional paid in capital | 284 | 263 | 259 | 252 | 249 | 247 | 247 | ||
| Accumulated deficit | (271) | (257) | (249) | (241) | (218) | (220) | (220) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total stockholders' equity: | 13 | 6 | 10 | 11 | 31 | 28 | 27 | ||
| TOTAL LIABILITIES AND EQUITY: | 57 | 34 | 41 | 45 | 53 | 52 | 58 | ||
Income statement (P&L) ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 0 | 0 | 0 | 0 | 0 | |||
| Operating expenses | (14) | (12) | (11) | (12) | (9) | (6) | (8) | |
| Operating loss: | (14) | (12) | (11) | (12) | (9) | (6) | (8) | |
| Nonoperating income (expense) | (0) | 4 | 3 | (11) | 4 | 7 | (3) | |
| Investment income, nonoperating | 2 | 1 | (3) | (0) | ||||
| Interest and debt expense | (0) | (0) | (1) | (0) | (0) | (0) | ||
| Loss from continuing operations before equity method investments, income taxes: | (14) | (8) | (9) | (24) | (5) | (0) | (11) | |
| Other undisclosed income from continuing operations before income taxes | 1 | 2 | ||||||
| Loss from continuing operations before income taxes: | (13) | (8) | (9) | (24) | (4) | (0) | (11) | |
| Other undisclosed income from continuing operations | 7 | |||||||
| Income (loss) before gain (loss) on sale of properties: | (13) | (8) | (9) | (24) | 3 | (0) | (11) | |
| Other undisclosed net income (loss) | (1) | 1 | (1) | |||||
| Net income (loss): | (14) | (8) | (9) | (23) | 2 | (0) | (11) | |
| Other undisclosed net income attributable to parent | 0 | 0 | 0 | 0 | ||||
| Net income (loss) available to common stockholders, basic: | (14) | (8) | (8) | (23) | 2 | 0 | (11) | |
| Dilutive securities, effect on basic earnings per share | (2) | |||||||
| Net income (loss) available to common stockholders, diluted: | (14) | (10) | (8) | (23) | 2 | 0 | (11) | |
Comprehensive Income ($ in millions)
| 12/31/2019 Q4 | 9/30/2019 Q3 | 6/30/2019 Q2 | 3/31/2019 Q1 | 12/31/2018 Q4 | 9/30/2018 Q3 | 6/30/2018 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (14) | (8) | (9) | (23) | 2 | (0) | (11) | |
| Comprehensive income (loss), net of tax, attributable to parent: | (14) | (8) | (9) | (23) | 2 | (0) | (11) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.